Literature DB >> 9154366

What information do physicians receive from pharmaceutical representatives?

J Lexchin1.   

Abstract

OBJECTIVE: To assess the information pharmaceutical sales representatives provide to physicians. DATA SOURCES: A MEDLINE search from January 1966 to May 1996 was done using combinations of the terms pharmaceutical industry, drug information services, drug utilization, physician's practice patterns and prescriptions, and drugs. Studies identified from this search were supplemented by material from my personal library. STUDY SELECTION: Studies had to be conducted in industrialized countries, based on direct observations of actual physician and sales representative contacts, and reporting quantitative results on the quality of information transmitted. SYNTHESIS: Four studies were included. Representatives usually mentioned the indications for their drugs, but omitted safety information. Representatives' information frequently contained inaccuracies.
CONCLUSION: Sales representatives present only selected, usually positive, information about their products. Canadian doctors should not be passive recipients of information provided by sales representatives. Physicians who choose to continue to see representatives must critically compare the information they get from them with that contained in scientific publications.

Mesh:

Year:  1997        PMID: 9154366      PMCID: PMC2255515     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  12 in total

1.  Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary.

Authors:  M M Chren; C S Landefeld
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

2.  Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks.

Authors:  B Hodges
Journal:  CMAJ       Date:  1995-09-01       Impact factor: 8.262

3.  Content analysis of drug-detailing by pharmaceutical representatives.

Authors:  E Hemminki
Journal:  Med Educ       Date:  1977-05       Impact factor: 6.251

4.  "Disinformation" from pharmaceutical company representatives.

Authors:  M Gordon
Journal:  CMAJ       Date:  1990-06-01       Impact factor: 8.262

5.  Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff.

Authors:  N Lurie; E C Rich; D E Simpson; J Meyer; D L Schiedermayer; J L Goodman; W P McKinney
Journal:  J Gen Intern Med       Date:  1990 May-Jun       Impact factor: 5.128

6.  Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices.

Authors:  A D Bower; G L Burkett
Journal:  J Fam Pract       Date:  1987-06       Impact factor: 0.493

7.  Differential education concerning therapeutics and resultant physician prescribing patterns.

Authors:  M H Becker; P D Stolley; L Lasagna; J D McEvilla; L M Sloane
Journal:  J Med Educ       Date:  1972-02

8.  The role of commercial sources in the adoption of a new drug.

Authors:  M Y Peay; E R Peay
Journal:  Soc Sci Med       Date:  1988       Impact factor: 4.634

9.  The accuracy of drug information from pharmaceutical sales representatives.

Authors:  M G Ziegler; P Lew; B C Singer
Journal:  JAMA       Date:  1995-04-26       Impact factor: 56.272

10.  Effect of problem-based, self-directed undergraduate education on life-long learning.

Authors:  J H Shin; R B Haynes; M E Johnston
Journal:  CMAJ       Date:  1993-03-15       Impact factor: 8.262

View more
  19 in total

1.  Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: entanglement.

Authors:  Ray Moynihan
Journal:  BMJ       Date:  2003-05-31

2.  Teaching appropriate interactions with pharmaceutical company representatives: the impact of an innovative workshop on student attitudes.

Authors:  James L Wofford; Christopher A Ohl
Journal:  BMC Med Educ       Date:  2005-02-08       Impact factor: 2.463

3.  General practitioners and pharmaceutical sales representatives: quality improvement research.

Authors:  Geoffrey Spurling; Peter Mansfield
Journal:  Qual Saf Health Care       Date:  2007-08

4.  Residents and pharmaceutical representatives.

Authors:  J Lexchin
Journal:  Can Fam Physician       Date:  1998-07       Impact factor: 3.275

5.  On the Nature and Strategies of Organized Interests in Health Care Policy Making.

Authors:  Damien Contandriopoulos
Journal:  Adm Soc       Date:  2011-01-01

6.  Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States.

Authors:  Barbara Mintzes; Joel Lexchin; Jason M Sutherland; Marie-Dominique Beaulieu; Michael S Wilkes; Geneviève Durrieu; Ellen Reynolds
Journal:  J Gen Intern Med       Date:  2013-04-05       Impact factor: 5.128

7.  Direct-to-consumer prescription drug advertising and the public.

Authors:  R A Bell; R L Kravitz; M S Wilkes
Journal:  J Gen Intern Med       Date:  1999-11       Impact factor: 5.128

8.  Sources of information for new drugs among physicians in Thailand.

Authors:  Maneerat R Layton; Wanapa Sritanyarat; Supatra Chadbunchachai; Albert I Wertheimer
Journal:  Pharm World Sci       Date:  2007-08-21

9.  A cross-sectional evidence-based review of pharmaceutical promotional marketing brochures and their underlying studies: is what they tell us important and true?

Authors:  Roberto Cardarelli; John C Licciardone; Lockwood G Taylor
Journal:  BMC Fam Pract       Date:  2006-03-03       Impact factor: 2.497

10.  Risk factors for potentially inappropriate prescribing to older patients in primary care.

Authors:  Ivana Projovic; Dubravka Vukadinovic; Olivera Milovanovic; Milena Jurisevic; Radisa Pavlovic; Sasa Jacovic; Slobodan Jankovic; Srdjan Stefanovic
Journal:  Eur J Clin Pharmacol       Date:  2015-09-29       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.